STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMGN
  4. [Form 4] AMGEN INC Insider Trading Activity

Amgen (AMGN) director Ellen Kullman receives 665-share RSU equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. director Ellen Jamison Kullman received a grant of 665 shares of common stock as a stock-based award. The award was in the form of Restricted Stock Units (RSUs) under Amgen’s 2009 director incentive and equity incentive plans and vested immediately, with each vested RSU paid in one share of common stock rather than through an open-market purchase.

After this grant, Kullman directly holds a total of 14,535.9807 Amgen shares, which include 2,121 dividend equivalents (DEs) that are credited to her unvested RSUs and will be paid in shares as those RSUs vest, along with cash for any remaining fractional share amount.

Positive

  • None.

Negative

  • None.
Insider Kullman Ellen Jamison
Role null
Type Security Shares Price Value
Grant/Award Common Stock 665 $0.00 --
Holdings After Transaction: Common Stock — 14,535.981 shares (Direct, null)
Footnotes (1)
  1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
RSU grant size 665 shares Common Stock RSU award to director on May 19, 2026
Post-transaction holdings 14,535.9807 shares Total Amgen shares directly held after the grant
Dividend equivalents 2,121 DEs Credited to unvested RSUs and payable in shares upon vesting
Price per granted share $0.00 per share Compensation grant, not an open-market purchase
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program..."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
dividend equivalents (DEs) financial
"These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."
Equity Incentive Plan financial
"under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
deferral schedule financial
"Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kullman Ellen Jamison
(Last)(First)(Middle)
ONE AMGEN CENTER DRIVE
(Street)
THOUSAND OAKS CALIFORNIA 91320
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026A665A$014,535.9807(1)(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
2. These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
/s/ Ellen J. Kullman05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Amgen (AMGN) director Ellen Kullman report in this Form 4?

Ellen Kullman reported receiving 665 Amgen common shares through a Restricted Stock Unit grant. The award vested immediately and was issued at no cash cost, reflecting routine director equity compensation rather than an open-market stock purchase or sale.

How many Amgen (AMGN) shares does Ellen Kullman hold after this transaction?

After the grant, Ellen Kullman holds 14,535.9807 Amgen common shares directly. This total includes shares from vested RSUs and 2,121 dividend equivalents linked to unvested RSUs that will pay out in shares as they vest.

What are the terms of the RSU grant reported by Ellen Kullman at Amgen (AMGN)?

The RSUs were granted under Amgen’s 2009 director incentive and equity incentive plans and vested immediately. Each vested RSU is paid in one share of Amgen common stock, with no purchase price, and may be deferred under a director-elected deferral schedule.

What are dividend equivalents (DEs) mentioned in Ellen Kullman’s Amgen (AMGN) filing?

Dividend equivalents are credits tied to unvested RSUs that mirror dividends on Amgen stock. Kullman’s holdings include 2,121 DEs, which will be paid out as shares of common stock upon vesting, plus a cash payment for any remaining fractional share amount.

Was Ellen Kullman buying or selling Amgen (AMGN) stock on the market in this Form 4?

The Form 4 shows a grant of 665 RSU-based shares, not an open-market trade. The shares were awarded as director compensation at a reported price of $0.00 per share, so there was no market purchase or sale involved in this transaction.